Visit COSMED @ booth #12 during the N&G 2020 in London (UK) from the 27th to the 29th of August 2020.

During these exceptional times, we would like to inform you that COSMED is adapting to the COVID-19 situation with diligence and is trying to face this big challenge with determination.

We wanted to take a moment to share with our customers, partners and communities how COSMED is responding to this evolving situation.

COSMED Announces Acquisition of Innovision Technology to Expand Product Portfolio and Presence in the Nordic Markets.

COSMED headquartered in Rome, Italy, leading manufacturer of Metabolic and Body composition technologies, has acquired assets of Innovision ApS, a Danish Company with significant know-how and expertise in the design of products for Hemodynamic (Cardiac Output), Ventilation Heterogeneity (Lung Clearance Index) and Metabolic measurements (VO2Max).

COSMED is glad to announce the U.S. Food and Drug Administration (FDA) clearance of Q-NRG+ and Q-NRG, a metabolic monitoring device utilizing Indirect Calorimetry (IC) technology intended for the measurement of Resting Energy Expenditure (REE) in patients who are mechanically ventilated or spontaneously breathing.

The role and the value of cardiopulmonary exercise testing (CPET) in cardiology has been examined in this review study on the Journal of the American College of Cardiology.